enu Pharma

Executive Summary

enu Pharma is a Japanese preclinical biotech company developing highly selective antibody therapeutics targeting glycopeptides, a novel drug target class. Founded in 2019 and spun out from Hokkaido University, the company leverages proprietary glycan analysis and antigen presentation technologies to create treatments for diseases with limited therapeutic options, particularly in neuroscience. As a private company with 10–50 employees, enu Pharma is still in the early stages of development and has not publicly disclosed any lead candidates or financial details.

Upcoming Catalysts (preview)

• Q1 2027Preclinical Proof-of-Concept Data for Lead Antibody Candidate45% success
• Q3 2026Series A Financing Round60% success
• H2 2026Research Collaboration with Academic or Pharma Partner50% success